contraceptive ring Myring in Canada, which will be marketed under the brand name Haloette. After the successful introduction of Mithra’s novel contraceptive pill Nextstellis in 2021, Searchlight Pharma is delighted to announce the commercialization of Haloette and further enhance its women’s health portfolio. The Canadian vaginal contraceptive ring market is currently valued at around CAD $11.5 million (EUR 8 million) per year and is represented by the originator Nuvaring 2. Haloette is a new low cost alternative for women which was authorized by Health Canada in September last year and is now accessible in Canadian pharmacies.
Haloette was designed and manufactured by European women’s health specialist and innovator Mithra. It does not require refrigeration before being delivered to patients. This benefits both wholesalers and pharmacies by lowering transportation and storage expenditures and the requirement for cold chain storage. Additionally, it simplifies the process for distributors, pharmacists, and patients.
Mark Nawacki, President & CEO of Searchlight Pharma, expressed delight over the new collaboration. He said, “We are delighted to partner with Mithra once again in order to offer Canadian women an additional choice in addressing their contraception needs. Since making Haloette available across Canada this past December, interest has been very high, as evidenced by rapid product uptake at major wholesalers and pharmacy banners throughout Canada, as well as the many formulary listings with private and public payers, including the Public Prescription Drug Insurance Plan (RAMQ) in Quebec.”
Leon Van Rompay, CEO of Mithra, expressed excitement over the partnership with Searchlight. He said, “It’s thrilling to team up once again with Searchlight Pharma to bring innovative contraceptive alternatives to Canadian women. Just a few months after the Canadian launch of Nextstellis , we are now also providing women with access to the first generic product of a contraceptive ring in this first region in North America. Our Mithra CDMO pursues the production of all Myring commercial batch orders for a range of new commercial launches planned for 2022.”
